Monoclonal anti-HER2/neu immunoglobulin fractions alone did not exert detectable levels of ex-vivo anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) which is in direct accord with descriptions from previous investigations for anti-HER2/neu [22,23,44-47,50-54] and anti-EGFR [44] at 0-to-182 hours in populations of several different neoplastic cell types (Figure 4). This evidence concerns the gene ERBB2 and breast adenocarcinoma.